Abstract
RATIONALE: Use of inhaled corticosteroids (ICS) is associated with local oropharyngeal adverse events that can negatively impact treatment initiation and adherence. Ciclesonide (CIC) delivered via hydrofluoroalkane metered-dose inhaler is a new, effective ICS with low oral deposition (<1%) and high lung deposition (~52%). CIC is primarily converted in the lung to its active metabolite, desisobutyryl-ciclesonide (des-CIC). Des-CIC has high serum protein binding and high glucocorticoid receptor affinity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
